MEN1 and acute myeloid leukemia: As compared to the MV4;11 AML cell line and an AML patient-derived xenograft (PDX), which both demonstrated a prolonged response to menin inhibitors, the GMP-like program was significantly upregulated in the P9 AML patient sample that developed resistance (Fig. 8b).